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Abstract 
The aim of this work was to investigate the potential of pegylated poly(anhydride) 
nanoparticles to enhance the oral bioavailability of docetaxel (DTX). Nanoparticles 
were prepared after the incubation between the copolymer of methyl vinyl ether and 
maleic anhydride (Gantrez® AN), poly(ethylene glycol) (PEG2000 or PEG6000) and 
docetaxel (DTX). The oral administration of a single dose of pegylated nanoparticles to 
mice provided sustained and prolonged therapeutic plasma levels of docetaxel for up 
48-72 h. In addition, the relative oral bioavailability of docetaxel was around 32%. The 
organ distribution studies revealed that docetaxel underwent a similar distribution 
when orally administered encapsulated in nanoparticles as when intravenously as 
Taxotere®. This observation, with the fact that the clearance of docetaxel when loaded 
into the oral pegylated nanoparticles was found to be similar to that of intravenous 
formulation, suggests that docetaxel would be released at the epithelium surface and 
then absorbed to the circulation. 
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1. Introduction 1 
Docetaxel (DTX) is a semisynthetic taxoid, analogue of paclitaxel, derived from the European 2 
yew tree (Taxus bacata sp.) and it is one of the most effective drugs in chemotherapy.  It has 3 
proven to be useful against several types of cancers such as breast, ovarian, prostate, head 4 
and neck, gastric and non-small lung cancers [de Weger et al., 2014; Nieuweboer et al., 5 
2015].  The mechanism of action of DTX, like other taxanes, is based on the stabilization of 6 
the microtubule dynamics and thereby disruption of the cell cycle [Nieuweboer et al., 2015]. 7 
This is due to its stronger binding capability to tubulin, docetaxel shows about 2 to 4 times 8 
more cytotoxicity effect on tumor cells than that of paclitaxel [Jones, 2006]. Docetaxel 9 
(Taxotere® and generics) is formulated as a concentrated aqueous solution containing 10 
polysorbate 80 (Tween® 80). The presence of this non-ionic surfactant has been related with 11 
severe side effects in some patients, including anaphylactic hipersensitivity reactions and 12 
cumulative fluid retention [Tang et al., 2016]. In order to minimize allergic reactions, patients 13 
require premedication with antihistamines (H2) and corticosteroids [Kang et al., 2017]. 14 
Therefore, investigation of alternative intravenous formulations of docetaxel is underway, 15 
and several approaches based on conjugates with albumin [Esmaeili et al., 2009], 16 
nanoparticles [Cho et al., 2011; Hwang et al., 2008], liposomes [Deeken et al., 2013] and 17 
micelles [Dou et al., 2014] have been proposed. 18 
Another possibility for docetaxel administration would be the use of the oral route. An 19 
important argument for docetaxel oral delivery is that this route of administration facilitates 20 
the implementation of chronic regimens and other dosing schedules such as metronomic 21 
therapies. This is particularly interesting for cell cycle specific agents and compounds with a 22 
predominant cytostatic effect (e.g. docetaxel) [Jiang et al., 2010; Wu et al., 2011]. Moreover, 23 
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oral chemotherapy can provide an easy way for the patients to take the drug by themselves 24 
at home, which will reduce their medical expenses and improve their quality of life.  25 
Nevertheless, docetaxel has a poor oral bioavailability of about 8% in humans [Malingré et 26 
al., 2011] and less than 4% in rodents [Bardelmeijer et al., 2002]. The main reasons for this 27 
low and variable oral bioavailability of DTX are related to a high lipophilicity and a low 28 
permeability within the gut. In fact, docetaxel has poor aqueous solubility (4.93 μg/ml) and 29 
upon oral administration, intestinal uptake is seriously hampered by drug efflux through 30 
intestinal P-glycoprotein (P-gp) and systemic exposure is further limited by drug metabolism 31 
via cytochrome P450 (CYP) 3A [Kuppens et al., 2005; Malingré et al., 2001]. One of the most 32 
popular strategies to boost the oral bioavailability of docetaxel is the combination of an oral 33 
formulation of the taxane with inhibitors of both P-gp and CYP3A4. Therefore, different 34 
preclinical and clinical studies have demonstrated the validity of this idea based on the co-35 
administration of the anticancer drug with cyclosporine A [Chiou et al., 2002] or ritonavir 36 
and elacridar [Hendrikx et al., 2014]. However, the use of drugs that inhibit these enzymes 37 
and transporters involves potential risks. In order to minimize these side effects other 38 
inhibitors such as curcumin [Yan et al., 2010] or flavonoids [Yang et al., 2011] have been 39 
proposed. 40 
Another approach may be the use of pegylated poly(anhydride) nanoparticles. These 41 
nanoparticles based on the copolymer of methyl vinyl ether and maleic anhydride (Gantrez® 42 
AN), have demonstrated a good ability to improve the oral bioavailability of paclitaxel (up to 43 
10 times, compared with “naked” nanoparticles) [Zabaleta et al., 2012; Calleja et al., 2014]. 44 
These results may be explained by the capability of PEG coatings to confer a high stability in 45 
digestive fluids minimizing the interaction of these nanoparticles with lumen contents [Tobio 46 
et al., 2000]. Similarly, the coating of nanoparticles with poly(ethylene glycol)s (PEGs) would 47 
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yield nanoparticles with slippery properties that facilitate the passage of these carriers 48 
through the mucus layer which is covering and protecting the intestinal epithelium 49 
[Yoncheva et al., 2005; Inchaurraga et al., 2015]. In addition, PEGs possess the disturbing 50 
capability on the effect of both the intestinal P-glycoprotein efflux pump [Hugger et al., 51 
2002] and the cytochrome P450 [Johnson et al., 2002]. These activities may be of interest to 52 
promote the oral absorption of docetaxel. 53 
Therefore, the aim of this work was the evaluation of the capability of pegylated 54 
poly(anhydride) nanoparticles as oral carriers for docetaxel. For this purpose, pegylated 55 
nanoparticles containing DTX were optimised and orally administered to Balb/c mice in 56 
order to study the pharmacokinetics and tissue distribution of this anticancer drug. 57 
 58 
2. Materials and Methods  59 
2.1.   Materials 60 
Docetaxel (USP 30, grade 99.0%) and paclitaxel (USP 28, grade >99.5%) were supplied by 61 
21CECpharm (London, UK). Poly(methyl vinyl ether-co-maleic anhydride) or poly(anhydride) 62 
(PMV/MA) [Gantrez® AN 119; MW 200,000; density: 1.03 g/mL] was purchased from 63 
International Specialty Products ISP/Ahsland Inc. (KY, USA). Taxotere® from Sanofi-Aventis 64 
was provided by the Pharmacy Service of University Clinic of Navarra (Pamplona, Spain). 65 
Phosphate buffered saline (PBS), pancreatin and glycine were obtained from Sigma Aldrich 66 
(MO, USA). Poly(ethylene glycol) with MW of 2000 and 6000 Da (PEG2000 and PEG6000, 67 
respectively) and disodium edetate (EDTA) were provided by Fluka (Buchs, Switzerland). 68 
Pepsin, acetone, ethanol, t-buthylmethylether and acetonitrile were obtained from Merck 69 
(Darmstadt, Germany). Polysorbate 80 (Tween® 80) was supplied by Panreac (Barcelona, 70 
Spain). Deionised reagent water (18.2 MΩ resistivity) was prepared by a water purification 71 
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system (Wasserlab, Pamplona, Spain). The anaesthetic isoflurane (Isoflo®) was from 72 
laboratories Esteve (Barcelona, Spain). All others reagents and chemicals used were of 73 
analytical grade.   74 
2.2.   Preparation of poly(anhydride)nanoparticles 75 
Docetaxel (DTX) was encapsulated in either conventional [Arbos et al., 2003] or pegylated 76 
poly(anhydride) nanoparticles. Pegylated nanoparticles with either PEG2000 or PEG6000 77 
were prepared following the method published by Zabaleta et al. (2012) with minor 78 
modifications. 79 
2.2.1.   Docetaxel-loaded pegylated poly(anhydride) nanoparticles  80 
Briefly, either PEG2000 or PEG6000 (12.5 mg) were firstly dispersed in 3 mL acetone and 81 
added to a solution of acetone containing 100 mg Gantrez® AN. The resulting mixture was 82 
maintained under magnetic agitation. On the other hand, docetaxel was dissolved in 0.5 mL 83 
acetone and added to the polymers mixture. Then, the organic phase containing DTX, 84 
PVM/MA and PEG was incubated for a period of 1 hour under magnetic stirring at room 85 
temperature. Afterwards, nanoparticles were formed by the addition of 20 mL of a 86 
hydroalcoholic solution (50% ethanol) containing glycine (0.5% w/v) and disodium edetate 87 
(0.18% w/v). The mixture was maintained under agitation for 10 minutes. The organic 88 
solvents were eliminated by evaporation under reduced pressure (Büchi Rotavapor® R-144; 89 
Büchi, Postfach, Switzerland) and the nanoparticle suspensions were purified by tangential 90 
filtration in Vivaspin tubes (Vivascience Sartorius, Hannover, Germany; MW cut off: 300,000) 91 
at 4,000 xg for 15 min. The pellets were resuspended in water and the purification step was 92 
repeated again. Finally, the formulations were frozen and freeze-dried (Genesis 12 EL Freeze 93 
Dryer; Virtis, PA, USA) using sucrose (5%) as cryoprotector. The resulting nanoparticles were 94 
identified as DTX-NP2 (docetaxel-loaded pegylated nanoparticles with PEG2000) and DTX- 95 
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NP6 (docetaxel-loaded pegylated nanoparticles with PEG6000). 96 
Empty pegylated nanoparticles (NP2 and NP6) were prepared in the same way as described 97 
above but in absence of docetaxel and used as controls.   98 
2.2.2.   Docetaxel-loaded poly(anhydride) nanoparticles  99 
Ten mg of docetaxel were incubated with 100 mg Gantrez® AN under magnetic stirring at 100 
room temperature for 1 hour in 5 mL acetone. Then, nanoparticles were formed by the 101 
addition of 20 mL of a mixture of ethanol and water (1:1 by vol.) containing glycine (0.5% 102 
w/v) and disodium edetate (0.18% w/v). The organic solvents were eliminated by 103 
evaporation under reduced pressure and the resulting nanoparticles were purified and 104 
freeze-dried as described above. 105 
Empty poly(anhydride) nanoparticles (NP) were prepared in the same way but in the 106 
absence of docetaxel. For identification, the following abbreviations were used: NP, 107 
poly(anhydride) nanoparticles; DTX-NP, docetaxel-loaded poly(anhydride) nanoparticles. 108 
2.3.   Characterization of nanoparticles 109 
2.3.1.   Physico-chemical characterization 110 
The mean hydrodynamic diameter of the nanoparticles and their zeta potential were 111 
determined by photon correlation spectroscopy (PCS) and electrophoretic laser Doppler 112 
anemometry, respectively, using a Zetamaster analyzer system (Malvern Instruments Ltd., 113 
Worcestershire, UK). The diameter of the nanoparticles was determined after dispersion in 114 
ultrapure water (1:10) and measured at 25°C by dynamic light scattering angle of 90°C. The 115 
zeta potential was determined as follows: 200 μL of the samples were diluted in 2 mL of a 116 
0.1 mM KCl solution. The yield of the process was calculated by gravimetry as described 117 
previously [Arbos et al., 2003].  118 
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The morphological examination of the nanoparticles was carried out by field emission 119 
scanning electron microscopy (FESEM) and by energy-filtered transmission electron 120 
microscopy (EFTEM). For FESEM analysis, nanoparticles were washed before imaging by 121 
centrifugation to remove the cryoprotector. For this purpose, a small amount of the freeze-122 
dried nanoparticles was resuspended in ultrapure water and centrifuged at 27,000xg for 10 123 
min. Then, the supernatants were rejected and the obtained pellets were mounted on 124 
copper grids. FESEM was performed using a Zeiss ultra Plus electron microscopy (Carl Zeiss 125 
SMT, Oberdochen, Germany) operating between 1 a 2 Kv from 3 mm distance.  126 
EFTEM was performed in a Zeiss Libra 120 (Carl Zeiss SMT, Oberkochen, Germany) operating 127 
at 80 kv. For this purpose, 20 μL of a suspension of nanoparticles were deposited onto 128 
copper grids for 1 min and excess suspension was blotted off using filter paper. Finally, 129 
samples were stained with phosphotungstic acid at 2% for 15 sec. The excess of this solution 130 
was blotted off using filter paper and grids were air dried before observation. Images were 131 
adquired using a 2k bottom-mount SlowScanCCD with YAG scintillator high-resolution 132 
camera (TRS-system, Moorenweis, Germany).   133 
2.3.2.   X-ray photoelectron spectroscopy (XPS) 134 
Surface chemical composition of the nanoparticles was studied by X-ray photoelectron 135 
spectroscopy (XPS) in a SPECS SAGE HR 100 (SPECS, Berlin, Germany) spectrometer equipped 136 
with a Mg Kα (1253.6 eV) non-monochromatic source operated at 250 W. The take-off angle 137 
was fixed at 90º and the analyses were conducted at a pressure of ~108 mbar. The pass 138 
energy was set at 30 and 15 eV for the general survey and the high resolution scans, 139 
respectively. The step size was 0.5 eV for the survey spectra and 0.1 for the high-resolution 140 
spectra, respectively. Charge compensation was achieved with an electron flood gun in the 141 
analysis chamber. The XPS data were processed with casaXPS V2.3.15 software 142 
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(Casa Software Ltd., Teignmouth, UK). Spectra were calibrated with the C-C peak position 143 
fixed at 285.0 eV [Moulder et al., 1992] after a Shirley background subtraction. The fitting 144 
procedure was done constraining the peak widths (same width for all peaks on each 145 
element) while the peak positions and areas were set free. 146 
2.3.3.   Quantification of the amounts of PEG associated with nanoparticles 147 
The amount of PEG associated to the nanoparticles was determined by HPLC coupled to an 148 
evaporative light scattering detector (ELSD) [Inchaurraga et al., 2015], with minor 149 
modifications. Briefly, analysis was carried out in a model 1100 series Liquid 150 
Chromatography, Agilent (Waldbronn, Germany) coupled to an ELSD 2000  Alltech apparatus 151 
(Illinois, USA). Separation was carried out on a PL Aquagel-OH column (300 mm x 7.5 mm; 152 
particle size 5 μm) (Agilent, Wokingham, UK), in a gradient elution with methanol-water as 153 
mobile phase at a flow rate of 1 mL/min. ELSD conditions were set as follows: drift tube 154 
temperature was maintained at 110 ºC, nitrogen flow was set at 3 L/min and the gain was 1. 155 
For the quantification of PEG2000, ELSD conditions were modified as follows in order to 156 
achieve maximum sensitivity: the drift tube temperature was set at 90°C, the nitrogen flow 157 
was maintained at 3.2 L/min and the gain was set to 2. 158 
For analysis, supernatants collected during the purification step of the preparative process 159 
were centrifuged at 17,000 rpm for 20 min at 4ºC. Then, aliquots of the supernatants (20 μL) 160 
were injected onto the HPLC column. The amount of PEG associated to nanoparticles was 161 
calculated as the difference between the initially added amount of PEG to the solution of the 162 
polymer in acetone and the amount of PEG recovered in the supernatants. Each sample was 163 
assayed in triplicate and the results were expressed as the amount of poly(ethylene glycol) 164 
per mg of nanoparticle. 165 
2.3.4. Evaluation of the average PEG chain density and conformation state  166 
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The PEG surface density (dPEG), the average distance between two neighbouring PEG chains 167 
(D) and the Flory Radius were calculated following the procedure described previously 168 
[Inchaurraga et al., 2015]. Then, the conformation state of PEG on the surface of 169 
nanoparticles was calculated by comparing D and RF. In any case, it was assumed that all the 170 
nanoparticles were spherical and displayed the same size (the mean size calculated by PCS). 171 
Similarly, it was also assumed that the associated PEG (as calculated by HPLC) was localized 172 
on the surface of the nanoparticles. 173 
2.3.5.   Docetaxel content in nanoparticles 174 
The amount of docetaxel loaded in the nanoparticles was quantified by HPLC-UV. The 175 
analytical apparatus was an Agilent model 1200 series LC coupled to a diode-array detector 176 
(Agilent) set at 228 nm. The chromatographic system was equipped with a reversed-phase 177 
150 mm x 3 mm C18 Phenomenex Gemini column (particle size 5 μm; Phenomenex, CA, 178 
USA) and protected by a 0.5 μm precolumn filter. The mobile phase, pumped at 0.5 mL/min, 179 
was a mixture of phosphate buffer (0.01 M; pH 2.1) and acetonitrile (50:50 v/v). The column 180 
was placed at 30°C and the injection volume was 100 μL. Paclitaxel (PTX) was used as 181 
internal standard. Under these experimental conditions the run time was 16 min and 182 
paclitaxel and docetaxel eluted at 6.8 and 8.2 min, respectively. For the calculations, the 183 
standard curve of docetaxel was designed over the range between 1.25 and 320 μg/mL 184 
(r2!0.999). The limit of quantification was calculated as 60 ng/mL with a relative standard 185 
deviation of 4.5%. 186 
For analysis, nanoparticles were digested with acetonitrile (1:8 volume ratio). Samples were 187 
transferred into auto-sampler vials, capped and placed in the HPLC auto-sampler. Each 188 
sample was assayed in triplicate and the results were expressed as the amount of docetaxel 189 
(μg) per mg of nanoparticles. 190 
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The encapsulation efficiency (E.E) was calculated as follows: 191 
   E.E. (%) = (Qassociated/Qinitial) x 100   (Eq.1) 192 
 193 
Where Qinitial is the initial amount of DTX added and Qassociated is the amount of entrapped DTX 194 
in the nanoparticles, which is calculated by HPLC. 195 
2.4.   In vitro release study 196 
Release experiments were conducted, under sink conditions, at 37°C using simulated gastric 197 
(SGF; pH 1.2; pepsin 0.32% w/v) and intestinal (SIF; pH 6.8; pancreatin 1% w/v) fluids 198 
containing 0.5% of polysorbate 80 (Tween® 80) as solubilising agent for docetaxel. The 199 
studies were performed under agitation in a Vortemp 56TM Shaking incubator (Labnet 200 
International Inc., NJ, USA) after the dispersion of the nanoparticles in the appropriate 201 
medium. 202 
For each time point, 50 μg docetaxel formulated in nanoparticles were resuspended in 2 mL 203 
of the corresponding simulated fluid. The concentration of the nanoparticles in the release 204 
medium was adjusted in order to assess sink conditions for docetaxel.  The different 205 
formulations were kept in the SGF for 2 hours and for 14 hours in SIF. At different time 206 
points, sample tubes were collected and centrifuged at 27,000xg for 20 minutes. Finally, 207 
samples were filtered and the amount of docetaxel released from the formulations was 208 
quantified by HPLC (calibration curves of free docetaxel in supernatants obtained from SGF 209 
and SIF, r2!0.999). Release profiles were expressed in terms of cumulative release 210 
percentage, and plotted versus time. 211 
2.4.1.   Analysis of release data 212 
Data obtained from the in vitro release experiments were treated by various conventional 213 
mathematical models to determine the release mechanism of the drug from the 214 
nanoparticles. Based on the highest regression values (r2) for correlation coefficients for 215 
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formulations, the best-fit model was decided. For this purpose, the following models were 216 
used: the Korsmeyer-Peppas equation (Eq.2), the Higuchi equation (Eq.3), and zero-order 217 
equation (Eq.4).  218 
The Korsmeyer-Peppas model exponentially relates drug release with the elapsed time 219 
[Ritger and Peppas, 1987]: 220 
    Mt/M∞= KKP x tn     (Eq.2) 221 
 222 
In which Mt/M∞ is the fraction of released drug at time t, KKP is a constant incorporating the 223 
structural and geometric characteristics of the matrix, and n is the release exponent 224 
indicating the drug release mechanism. If “n” value is around 0.5 (the exact value depends 225 
on the geometry), the mechanism is Case I (Fickian) diffusion. A value between 0.5 and 0.89 226 
indicates anomalous (non-Fickian) diffusion and a value of 0.89 and above indicates a Case II 227 
Transport. 228 
When the release mechanism is mainly based on a Fickian diffusion, a dimensionless 229 
expression of the Higuchi model can be applied [Costa and Sousa, 2011]: 230 
    Mt/M∞= KH x t1/2     (Eq.3) 231 
 232 
Where Mt/M∞ is the fraction of released drug at time t, and KH is the Higuchi constant.  233 
Finally, the following zero-order kinetic model was also used. This model is used for systems 234 
where the matrix releases the same amount of drug by unit of time: 235 
Qt = Q0 + KZO x t   (Eq.4) 236 
 237 
Where Qt is the amount of drug dissolved in time t and Q0 is the initial amount of drug in the 238 
solution (most times, Q0= 0) and KZO is the zero-order release constant. 239 
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The analysis was applied to the release study of docetaxel performed under simulated 240 
intestinal fluid, until the 60-80% of drug released. All data processing was performed using 241 
Origin 8.0 software (OriginLab Corporation, MA, USA). 242 
2.5.   Pharmacokinetic studies  243 
Pharmacokinetic studies were carried out in Balb/c female mice (average weight 19-22 g) 244 
obtained from Harlan (Santiga, Spain). Studies were approved by the Ethical Committee for 245 
Animal Experimentation of the University of Navarra (protocol number E21-12) in 246 
accordance with the European legislation on animal experiments (86/609/EU). Before the 247 
experiment, animals were adaptively fed for 1 week with free access to food and drinking 248 
water (22 ± 2°C; 12-h light and 12-h dark cycles; relative humidity 55 ± 10%). Previous to the 249 
oral administration of the formulations, animals were fasted overnight to avoid the 250 
interference with the absorption, allowing free access to water. 251 
For the pharmacokinetic study, the animals were randomly divided into five groups. The 252 
experimental groups were as follows: (a) DTX-NP2, (b) DTX-NP6 and (c) DTX-NP. As controls, 253 
one group of animals received Taxotere® intravenously and another group was treated with 254 
the commercial formulation orally. Each animal received the equivalent amount of docetaxel 255 
to a dose of 30 mg/kg body weight (bw) either orally with a blunt needle via the esophagus 256 
into the stomach or intravenously via tail vein as a slow infusion. All the formulations were 257 
administered dispersed or dissolved in either purified water (oral) or sterile saline 258 
(intravenous). All animals were observed for their general condition and clinical signs. 259 
At established times after administration, blood was obtained from 4 animals in each group. 260 
EDTA was used as an anticoagulant agent. Blood volume was recovered intraperitoneally 261 
with an equal volume of normal saline solution preheated at body temperature. Samples 262 
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were immediately placed on ice and centrifuged at 2,500xg for 10 minutes. Plasma was 263 
separated into clean tubes and kept frozen at -80ºC until HPLC analysis.  264 
2.5.1.   Determination of DTX plasma concentration by HPLC-UV 265 
The amount of docetaxel was determined in plasma by HPLC-UV as described above. The 266 
extraction method was adapted from Zhao et al. (2010). Calibration curves were used for the 267 
conversion of the DTX/PTX chromatographic area to the concentration. Calibrator and 268 
quality control samples were prepared by adding appropriate volumes of standard docetaxel 269 
in ethanol to drug free plasma. Calibration curves were designed over the range between 270 
100 and 3200 ng/mL (r2>0.999). An aliquot (200 μL) of plasma was mixed with 25 μL of 271 
internal standard solution (paclitaxel, 10 μg/mL in ethanol). After vortex mixing, liquid–liquid 272 
extraction was accomplished by adding 3 mL of tert-buthylmethylether following vortex 273 
gentle agitation (10 min). The mixture was centrifuged for 10 min at 2,500xg, and then, the 274 
organic layer was transferred to a clean tube and evaporated to dryness (Thermo Savant, 275 
Barcelona, Spain). The residue was then dissolved in 125 μL of reconstitution solution 276 
(acetonitrile–phosphate buffer; 0.01 M; pH 2.1; 50:50 v/v) and transferred to auto-sampler 277 
vials, capped and placed in the HPLC auto-sampler. A hundred microlitre-aliquot of each 278 
sample was injected onto the HPLC column. 279 
Under these experimental conditions the UV detection of docetaxel was performed at 228 280 
nm and the run time was 16 min. The limit of quantification was calculated to be 140 ng/mL 281 
with a relative standard deviation of 5.3%. Accuracy values during the same day (intraday 282 
assay) at low, medium and high concentrations of docetaxel were always within the 283 
acceptable limits (less than 5%) at all concentrations tested. 284 
2.5.2.   Pharmacokinetic data analysis 285 
The pharmacokinetic analysis of plasma concentration plotted against time data, obtained 286 
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from the administration of the different docetaxel formulations, was performed based on a 287 
non-compartmental model using WinNonlin 5.2 software (Pharsight Corporation, MO, USA). 288 
The following parameters were estimated: maximal plasmatic concentration (Cmax), time in 289 
which the maximum concentration is reached (Tmax), area under the concentration-time 290 
curve from time 0 to t h (AUC), mean residence time (MRT), clearance (Cl), volume of 291 
distribution (V) and half-life of the terminal phase (t1/2z). In addition, the relative oral 292 
bioavailability (Fr) of docetaxel was calculated using the ratio of dose-normalized AUC values 293 
following oral and i.v. administrations: 294 
    Fr (%)=AUCoral/ AUCi.v x 100   (Eq.5) 295 
Where AUCoral and AUCi.v.  correspond to the areas under the plasma curve for the oral and 296 
intravenous (Taxotere®) administrations, respectively. 297 
2.6.   Organ distribution of docetaxel 298 
To study the amount of anticancer drug in different organs after administration, animals 299 
received docetaxel loaded in the poly(anhydride) nanoparticles orally at a dose of 30 mg/kg.  300 
Treatment groups were DTX-NP, DTX-NP2 and DTX-NP6. In addition, a group of mice was 301 
treated intravenously with the commercial formulation, Taxotere®, at the same dose (30 302 
mg/kg) as control. After administration, mice were sacrificed at different time points by 303 
cervical dislocation under isoflurane anesthesia (n=4 at each time point) and the following 304 
organs were harvested: liver, spleen, kidneys, lung, heart, stomach and intestine. In the 305 
group receiving the commercial formulation, animals were sacrificed at 4, 12 and 24 hours 306 
post-administration. The animals treated with the pegylated-poly(anhydride) nanoparticles 307 
(DTX-NP2 and DTX-NP6) were sacrificed at 8, 24 and 72 hours post-administration. Finally, 308 
for the DTX-NP group, the animals were killed at 8 h post-administration exclusively. Times 309 
points were selected based on the plasmatic curves obtained for the different formulations 310 
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in mice. 311 
Each tissue simple was kept on ice, accurately weighted in polystyrene tubes and 312 
homogenized in 1 ml of PBS pH 7.4 using a Mini-bead beater (BioSpect Products Inc, OK, 313 
USA). Later, the homogenized organs were centrifuged at 10,000xg for 10 minutes. The 314 
supernatants were then collected and stored at -80°C until further analysis by the HPLC 315 
assay. 316 
The amount of docetaxel in each tissue was determined by liquid-liquid extraction method 317 
followed by reverse-phase HPLC analysis. The method for the extraction was adapted from 318 
Zhao et al. (2010). Standardized calibration curves were used for each organ. As internal 319 
standard, paclitaxel was used and the conversion of the DTX/PTX chromatographic areas to 320 
concentration was performed. 321 
For extractions, aliquots (200 μL) of the selected tissue samples were mixed with 25 μL PTX 322 
solution (10 μg/mL ethanol) for 1 min. Then, 3 ml t-buthylmethylether was added, and the 323 
resulting mixtures were vortex-mixing for 10 min. Next the mixture was centrifuged at 324 
2,500xg for 10 min and the clear organic layer was transferred to a clean tube and 325 
evaporated until complete dryness. Finally, the residue was reconstituted with 125 μL of 326 
acetonitrile-phosphate buffer (0.01 M; pH 2.1; 50:50 v/v) and quantified by HPLC-UV. 327 
2.7.   Statistical analysis 328 
Data are expressed as the mean ± S.D of at least three experiments. The non-parametric 329 
Kruskal-Wallis followed by U Mann-Whitney test was used to investigate statistical 330 
differences. In all cases, p values less than 0.05 were considered to be statistically significant. 331 
All calculations were performed using GraphPad Prism 6.0 statistical software (GraphPad 332 
Software, CA, USA). 333 
 334 
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3. Results 335 
3.1.   Preparation and characterization of poly(anhydride) nanoparticles 336 
Table 1 summarizes the main physico-chemical properties of the different poly(anhydride) 337 
nanoparticles used in this work. Overall, pegylation of DTX-loaded nanoparticles slightly 338 
decreased the mean size (220 nm for conventional and about 200 nm for pegylated 339 
nanoparticles) and the negative zeta potential of the resulting nanoparticles (-43 mV vs. -35 340 
mV). Besides, the polydispersity index (PDI) was lower than 0.2 and the yield of the process 341 
was calculated to be between 60 and 65%. Empty nanoparticles displayed similar physico-342 
chemical characteristics than the DTX-loaded ones except for the yield of the process which 343 
was slightly higher than in the presence of the anticancer drug (between 70 and 80%). 344 
Similarly the mean size of empty nanoparticles was found to be slightly smaller than in the 345 
presence of docetaxel (see Table 1).  346 
In addition, the amounts of PEG associated with the poly(anhydride) nanoparticles were 347 
quantified by HPLC-ELSD. The analysis revealed that the amount of PEGs associated to 348 
nanoparticles was significantly higher when nanoparticles were pegylated with PEG6000 349 
(a55 µg/mg) than with PEG2000 (a40 µg/mg) (p<0.05). Based on these calculations, the 350 
estimated values of PEG densities on the surface of nanoparticles decreased with increasing 351 
the length of the PEG chain. Thus, dPEG was about 3-times higher for nanoparticles pegylated 352 
with PEG2000 than when PEG6000 (0.46 vs. 0.15 nm-2). On the other hand, as for both types 353 
of nanoparticles D was smaller than the Flory Radius (data not shown), the PEG chains 354 
adopted a “brush” conformation on the surface of both pegylated nanocarriers.    355 
Regarding the amount of docetaxel loaded in the nanoparticles, the addition of glycine to 356 
conventional nanoparticles enhanced dramatically the docetaxel loading, making it 20-times 357 
higher than when conventional nanoparticles were prepared in absence of this amino acid 358 
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(data not shown). For conventional nanoparticles, docetaxel content was estimated in 60 μg 359 
DTX/mg NP. However, for pegylated nanoparticles (DTX-NP2 and DTX-NP6), the docetaxel 360 
payload significantly increased. Thus, for nanoparticles pegylated with PEG6000 the DTX 361 
content was around 90 μg DTX/mg NP, whereas for DTX-NP2 the drug loading was almost 2-362 
times higher than for “nacked” nanoparticles (approx. 111 μg/mg NP). The encapsulation 363 
efficiency for DTX-NP2 and DTX-NP6 nanoparticles was 60 and 78%, respectively, whereas 364 
for DTX-NP it was about 42%. 365 
Figure 1 shows the microphotographs obtained by field emission scanning and energy-366 
filtered transmission electron microscopy of the nanoparticles. In all cases, the apparent 367 
sizes of nanoparticles were similar to the values obtained by photon correlation 368 
spectroscopy. All the nanoparticles formulations displayed spherical shapes. Moreover, 369 
conventional nanoparticles presented a smooth or plain surface (Figure 1A) whereas 370 
pegylated ones appeared to show a spongy and diffuse surface (Figures 1B and 1C). In 371 
addition, from EFTEM analysis (Figure 1D), pegylated nanoparticles appeared as spherical 372 
structures surrounded by a long and diffuse dark area. 373 
X-ray photoelectron spectroscopy (XPS) technique quantified the elemental and average 374 
chemical composition by measuring the binding energy of electrons associated with atoms 375 
around 5-10 nm depth inside the polymeric surface. Fittings of the C1s spectra (atomic 376 
orbital 1s of carbon) of the surface of the poly(anhydride) nanoparticles and its components 377 
were examined (Table 2). Comparing the different control nanoparticles (NP, NP2 and NP6), 378 
when PEG was incorporated to the formulation, the content of C-O bonds progressively 379 
increased from NP (11%) to NP2 (19%) and NP6 (21%) while the proportion of C=O and C-380 
C/C-H bonds decreased. For the docetaxel-loaded formulations (DTX-NP, DTX-NP2 and DTX-381 
NP6), the addition of PEG induced a decrease of the signal related to the presence of C=O 382 
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bonds (15% for DTX-NP and 8% for DTX-NP6). In parallel, pegylation of nanoparticles 383 
produced an important increase on the percentage of C-O bond values and a decrease of the 384 
C-C/C-H intensity (Table 2).  385 
Regarding the surface elemental composition (in atomic percentage values) of the samples, 386 
the carbon and oxygen content was very similar in all control formulations (NP, NP2 and 387 
NP6). However, the nitrogen signal is only detected in loaded-DTX nanoparticles (DTX-NP, 388 
DTX-NP2 and DTX-NP6). Thus, the nitrogen content progressively decreased when PEG was 389 
added to these loaded formulations while the oxygen content increased. 390 
3.2.   In vitro release study 391 
Figure 2 depicts the release profiles of docetaxel from the different formulations expressed 392 
as cumulative percentage of drug released as a function of time. In all cases, when 393 
nanoparticles were incubated in SGF, no drug release was observed. In contrast, when 394 
nanoparticles were dispersed in the SIF, docetaxel was released. For DTX-NP2 the release 395 
pattern in SIF was characterized by an important burst effect of about 75% of the loaded 396 
drug in the first 30 min followed by a more sustained deliverance phase up to 10 hours. On 397 
the other hand, for DTX-NP and DTX-NP6, the release curves of docetaxel in SIF exhibited a 398 
slower discharge of docetaxel than DTX-NP2 followed by a more steady release up to the 399 
end of the study in which almost all of their cargo was extracted. In any case, 1 h after the 400 
incubation of nanoparticles in SIF, the amount of docetaxel released from DTX-NP6 was 401 
about 65% of the loaded drug whereas for DTX-NP, only 55% of the drug was released. 402 
The release profiles of DTX from nanoparticles were evaluated by fitting the in vitro data into 403 
various kinetic models (Table 3). For DTX-NP and DTX-NP2, the experimental data of the 404 
docetaxel release in SIF fitted well into the Korsmeyer-Peppas equation (Eq.2) with 405 
regression coefficients higher than 0.98. For both nanoparticle formulations, the release 406 
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exponent (n) was calculated to be lower than 0.5. For DTX-NP6, the data were adequately 407 
adjusted to the three models. The obtained r2 values for these models were around 0.8. 408 
However, the calculated “n” value in the Korsmeyer-Peppas equation, was about 0.8 (Table 409 
3).  410 
3.3.   Pharmacokinetic studies  411 
The plasma concentration-time profile of docetaxel after iv administration of Taxotere® 412 
(single dose of 30 mg/Kg) to female Balb/c mice is shown in Figure 3. The drug plasma 413 
concentration rapidly decreased in a biphasic way with time and data were adjusted to a 414 
non-compartmental model. Levels of docetaxel in plasma were quantifiable until 12 hours 415 
post-administration. The estimated AUC was 140 μg h/ml with a maximum concentration 416 
(Cmax) of 198 μg/mL. The mean residence time (MRT) and the half-life of the terminal phase 417 
(t1/2z) were estimated to be 1.5 hours. The clearance (Cl) of docetaxel was 0.2 L/h/kg and the 418 
volume of distribution (V) of the drug was about 0.5 L/kg (Table 4). 419 
Figure 4 shows the plasma concentration versus time profiles after oral administration of 420 
docetaxel (single dose of 30 mg/kg) to Balb/c mice when administered as commercial 421 
Taxotere® or encapsulated in the different poly(anhydride) nanoparticle formulations. When 422 
Taxotere® was orally administered to mice, docetaxel plasma levels were found to be always 423 
below the quantification limit of the chromatographic analytical technique. On the contrary, 424 
when docetaxel was loaded in nanoparticles, these formulations displayed sustained plasma 425 
levels. In all cases, there was an initial rapid rise in the anticancer plasma levels for the first 2 426 
hours, reaching the Cmax, this was followed by a slow decline which was prolonged for at 427 
least 8 hours for DTX-NP, and about 70 hours for the PEG containing formulations (DTX-NP2 428 
and DTX-NP6). Comparing DTX-NP2 with DTX-NP6, DTX-NP2 provided slightly higher levels of 429 
the anticancer drug than those determined for DTX-NP6. Another important fact to highlight 430 
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was that, for both nanoparticle formulations, the docetaxel plasma levels were within the 431 
therapeutic window. For docetaxel, in rodents, this therapeutic window would be between 432 
35 ng/mL (minimum effective dose) and 2700 ng/mL (maximum tolerated dose) [Mei et al., 433 
2013]. 434 
Table 4 summarizes the pharmacokinetic parameters calculated with a non-compartmental 435 
analysis of the experimental data obtained after the administration of the different 436 
docetaxel formulations to mice. For DTX-NP2 and DTX-NP6, AUC values were respectively 6.5 437 
and 5-fold higher than the AUC obtained for non-pegylated nanoparticles (DTX-NP), 438 
demonstrating a higher capability to promote the oral absorption of the taxane. In addition, 439 
Cmax values of docetaxel in the poly(anhydride) nanoparticles was between 1.3 and 2 μg/ml. 440 
The rank order of this parameter was DTX-NP6 > DTX-NP2 > DTX-NP. Moreover, the Cmax was 441 
reached at 0.08 h for DTX-NP,1.5-2 h for DTX-NP6 and DTX-NP2. Furthermore, the mean 442 
residence time (MRT) of the drug in plasma and the half-life of the terminal phase (t1/2z) 443 
were found to be similar for pegylated nanoparticles (both DTX-NP2 and DTX-NP6). 444 
Interestingly, for all the formulations and routes of administration tested, the clearance of 445 
docetaxel displayed a similar value (about 0.2 L/h/kg). On the contrary, the volumen of 446 
distribution (V) of the anticancer drug was about 10 times higher when loaded in pegylated 447 
nanoparticles than for DTX-NP and Taxotere® intravenously administered. Finally, the 448 
relative oral bioavailability of docetaxel delivered in pegylated nanoparticles was calculated 449 
to be around 24% for DTX-NP6 and 32% DTX-NP2. For control nanoparticles, the oral 450 
bioavailability was found to be of about 5%.  451 
3.4. Organ distribution of docetaxel 452 
Organ distribution of docetaxel was evaluated in Balb/c mice after the administration of a 453 
single dose (30 mg/kg) either intravenously as Taxotere® or orally after encapsulation in 454 
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nanoparticles. Figure 5 summarises the levels of the anticancer drug in the different organs 455 
at different times after administration. For i.v. Taxotere®, the highest concentration of 456 
docetaxel 4 h post-administration was found in the spleen (about 31 µg DTX/g tissue) and 457 
the liver (about 24 µg DTX/g tissue). Also, an important and similar amount of drug was 458 
quantified in the kidneys, lung and heart (about 16-18 µg DTX/g tissue). These levels 459 
decreased rapidly with time and 24 h post-administration only significant amounts of 460 
docetaxel were quantified in spleen (about 10 µg DTX/g tissue). 461 
For DTX-NP2 and DTX-NP6 orally administered, the amount of the drug recovered in the 462 
different organs of animals was similar for both formulations. Thus, 24 hours after 463 
administration, docetaxel was mainly found in spleen and liver (a20 µg DTX/g tissue), 464 
followed by intestine (a18 µg DTX/g tissue), lung and kidneys (a13 µg DTX /g tissue). As time 465 
increased, the drug amounts in tissues decreased, even so, 72 hours post-administration 466 
significant amounts of docetaxel were still quantified in the spleen, lung and kidneys (about 467 
5 µg DTX /g tissue). 468 
Figure 6 represents the amount of docetaxel recovered in different organs of animals 8 h 469 
after the administration of a single dose of the anticancer drug (30 mg/kg) formulated in 470 
nanoparticles or as Taxotere®. Overall, 8 h post-administration the amounts of anticancer 471 
drug found in the liver, lungs and gut for pegylated nanoparticles (DTX-NP2 and DTX-NP6), 472 
were higher than for Taxotere®. Thus, the liver of animals treated with docetaxel orally as 473 
pegylated nanoparticles displayed 3-times more drug than when intravenously administered 474 
as Taxotere®. By contrast, 8 h post-administration, the levels of docetaxel when 475 
administered in conventional nanoparticles (DTX-NP) were dramatically low, close to the 476 
quantification limit of the HPLC technique (280 ng/mL).  477 
Focusing on the differences observed amongst nanoparticles, there were not significant 478 
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differences between DTX-NP2 and DTX-NP6 for all the organs tested.  479 
 480 
4. Discussion 481 
The oral bioavailability of taxanes (e.g. docetaxel) is hampered by both their high lipophilic 482 
character and low permeability related to their affinity to the P-glycoprotein and 483 
cytochrome P450 enzymatic complex [Wu et al., 2011; Malingré et al., 2001]. In order to 484 
solve these problems and thus enhance the oral absorption of these drugs, one possible 485 
solution may be the encapsulation of these drugs into polymeric nanoparticles with both 486 
mucus-penetrating properties and inhibitory abilities of the efflux pump activity and 487 
cythocrome P450 metabolism. The pegylation of nanoparticles from the copolymer of 488 
methyl vinyl ether and maleic anhydride yields submicronic carriers with these capabilities 489 
[Yoncheva et al., 2005; Inchaurraga et al., 2015]. In addition, acute and sub-acute toxicity 490 
studies in rats clearly demonstrated the absence of toxic or side effects when these 491 
nanoparticles were orally administered [Ojer et al., 2012]. In the present work, our aim was 492 
to gain more insight about the structure and composition of these pegylated nanoparticles 493 
as well as explore their potential as oral delivery systems for docetaxel. 494 
Pegylation of poly(anhydride) nanoparticles slightly decreased the mean size and the 495 
negative zeta potential of “naked” nanoparticles (Table 1). Furthermore, the amount of PEG 496 
associated to the nanoparticles was significantly higher when nanoparticles were pegylated 497 
with PEG6000 than with PEG2000. This observation is in line with previous reported data 498 
[Zabaleta et al., 2012; Inchaurraga et al., 2015], in which it was described a higher degree of 499 
pegylation by increasing the MW of the PEG. All PEG-coated nanoparticles used have their 500 
PEG chains in a “brush” conformation, independent of the PEG chain molecular weight.  501 
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Regarding the encapsulation of docetaxel in nanoparticles, glycine and EDTA were employed 502 
to increase its loading into the resulting nanoparticles. Thus, when the amino acid and the 503 
chelating agent was added to the medium in which the nanoparticles were obtained, the 504 
drug loading was about 20-30 times higher than in the absence of both auxiliary excipients 505 
(about 3 µg/mg nanoparticles). The chelating agent would prevent the opening of the 506 
anhydride groups by the presence of bivalent cations, whereas glycine would promote the 507 
encapsulation of docetaxel in the resulting nanoparticles. In fact, the addition of glycine 508 
would alter the solvent properties of the mixture in which the nanoparticles are formed, 509 
decreasing the solubility of the polymer in this medium and facilitating the interaction 510 
between the polymer and docetaxel by hydrophobic bonds. A similar effect has been 511 
observed by adding glycine to different kinds of micelles, generating important increases of 512 
their capability to load hydrophobic compounds (i.e., quercetin) [Ruiz et al., 2008; Pillai et 513 
al., 2016]. 514 
On the other hand, the docetaxel loading was also found to be dependent on both the 515 
presence and MW of PEG employed for pegylation. In this way, the use of PEG2000 allowed 516 
us to increase almost 2-times the docetaxel payload compared to “naked” nanoparticles. 517 
These results agree well with previous studies with PLGA/PLA particles [Enolw et al., 2011], 518 
which reported a significant increase of docetaxel loading in pegylated PLGA/PLA delivery 519 
systems, in comparison with the conventional ones, due to the solubilising properties of 520 
PEG. In addition, PEG2000 appeared to be slightly superior for increasing the docetaxel 521 
entrapment in poly(anhydride) nanoparticles.  522 
From the observations by electronic microscopy techniques (Figure 1), these pegylated 523 
nanocarriers would adopt a structure based on a solid core surrounded by a PEG corona. In 524 
order to study this structure, the surface of nanoparticles was examinated by XPS analysis 525 
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(Table 2). Comparing “naked” nanoparticles (NP) with pegylated ones (NP2 and NP6), the 526 
percentage of C-O bonds, which are typical in the poly(ethylene glycol) structure [Baer and 527 
Engelhard, 2010], increased after nanoparticle pegylation. In addition, NP6 produced a 528 
slightly more intense signal of C-C/C-H bonds than NP2. This observation would be related to 529 
a longer C-C/C-H chain for PEG6000 than for PEG2000.  When docetaxel was loaded into 530 
“naked” nanoparticles (DTX-NP), an increase in the XPS signals related with the presence of 531 
C-N bonds was found. This fact would be due to the presence of both the anticancer drug 532 
and glycine. Additionally, the presence of docetaxel and glycine also induces a reduction in 533 
the percentages of C-C/C-H and C=O bonds, as compared with NP. For pegylated 534 
nanoparticles, the presence of PEG at the surface of nanoparticles would hinder the access 535 
and, therefore, the binding of glycine to the surface of nanoparticles. In the case of DTX-NP2, 536 
this finding would be supported by a decrease of the nitrogen content for these 537 
nanoparticles (as compared with DTX-NP) as well as by the decrease in the percentage of C-538 
N/C-O bonds that can be attributed to the substitution of glycine by PEG. Finally, for DTX-539 
NP6, elemental analysis displayed a very low amount of nitrogen associated with a high 540 
content of oxygen. In addition, these nanoparticles showed a low percentage of C=O and C-541 
C/C-H bonds and a quite high content of C-N/C-O bonds. These last observations would be 542 
related to the presence of the PEG chains at the surface of nanoparticles. To sum up, the 543 
reduction of the nitrogen content would be associated to the presence of PEG in the 544 
samples. In addition, the presence of longer PEG chains would be reflected by an increase in 545 
the percentage of C-N/C-O bonds. Moreover, the decrease in the percentage of C=O bonds 546 
(typical for anhydride residues) observed for pegylated nanoparticles (mainly for those 547 
pegylated with PEG 6000) would be directly related to the particular characteristics of the 548 
XPS technique, which is adapted to the investigation of the surface properties of a given 549 
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material [Baer and Engelhard, 2010]. All together would probe that pegylation of these 550 
poly(anhydride) nanoparticles yields a PEG coating.  551 
Docetaxel release profiles from nanoparticle formulations were evaluated in simulated 552 
gastric and intestinal fluids, both containing Tween 80 as solubilising agent. In all cases, no 553 
drug release was observed when nanoparticles were incubated in acid conditions. However, 554 
under simulated intestinal pH conditions, docetaxel was rapidly released with small 555 
differences between “naked” and pegylated nanoparticles. Thus, pegylated nanoparticles 556 
displayed profiles characterized by an initial release pulse of 65-75% of the loaded drug 557 
followed by a slow deliverance phase of the remaining drug. For DTX-NP, the curve was 558 
characterized by an initial burst effect of about 40% followed by a sustained and continuous 559 
release step. Interestingly, the release pulse was almost immediate for DTX-NP2 formulation 560 
whereas, for nanoparticles pegylated with PEG6000 the burst effect only appeared after 1 h 561 
of incubation in SIF. Analysis of the release data also highlighted a different behaviour 562 
between nanoparticle formulations. The release of docetaxel from DTX-NP and DTX-NP2, 563 
characterised by a Korsmeyer-Peppas exponent coefficient lower than 0.5, would be 564 
explained by a quasi-Fickian Higuchi diffusion mechanism, typical of matrix-type devices. On 565 
the contrary, the mechanism involved in the release of docetaxel from DTX-NP6 (with a 566 
Korsmeyer-Peppas coefficient of 0.8) would be a combination between diffusion and 567 
erosion. In this case, the presence of long chains of poly(ethylene glycol) at the surface of 568 
the nanoparticles would hamper the diffusion of the loaded drug. So the release of the 569 
loaded drug will be delayed until the nanoparticle matrix will start to be eroded/dissolved. 570 
For the pharmacokinetic study in mice, a single dose of 30 mg docetaxel per kg bw was 571 
selected. Taxotere®, intravenously administered, presented a characteristic nonlinear profile 572 
(Figure 3) that has been previously reported by other authors [Nieuweboer et al., 2015; Van 573 
  26 
Tellingen et al., 1999] and associated with the effect of micellar entrapment on DTX in 574 
presence of Tween® 80 in the formulation, which could affect the distribution of unbound 575 
drug [Nassar et al., 2011; Desai et al., 2008]. At the administered dose, the plasmatic levels 576 
of docetaxel diminished rapidly, and 12 hours post-administration, no levels of the drug 577 
were quantified. The non-linearity was caused mainly during the first hours after drug 578 
administration when the concentrations were relatively high. From this curve, the mean AUC 579 
and the half-life of the terminal phase (t1/2z) for docetaxel were estimated to be about 140 580 
µg h/ mL and 1.5 hours, respectively. The volume of distribution (V) was 0.5 L/h and 581 
clearance (Cl) was 0.2 L/h/kg. These results are consistent with data previously published by 582 
Van Tellingen et al. (1999), who administered Taxotere® at similar dose level (33 mg 583 
docetaxel per kg bw) in female FVB mice. In contrast, when commercial Taxotere® was 584 
administered orally, the drug plasma levels were below the quantification limit of our 585 
technique. In any case, the oral bioavailability of docetaxel in mice has been previously 586 
reported to be around 3.6% [Bardelmeijer et al., 2002]. 587 
When docetaxel was orally administered after encapsulation in pegylated nanoparticles, the 588 
plasma levels of the anticancer drug were high and sustained in time till 3 days. For “naked” 589 
nanoparticles, the docetaxel plasma concentration was initially high but decreased rapidly 590 
and no quantifiable levels were found 12 h after administration. More importantly, the 591 
docetaxel plasma levels provided by pegylated nanoparticles were found to be within the 592 
therapeutic window [Saremi et al., 2011; Mei et al., 2013]. This observation is particularly 593 
interesting for an oral docetaxel treatment that would permit to achieve long-term drug 594 
exposure and predicted responses [Bruno et al., 1998]. Moreover, the half-life of the drug 595 
was greatly extended from 1.5 h for intravenous administration to 35 h for oral 596 
administration of pegylated nanoparticles (Table 4). This may be due to the capability of 597 
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pegylated nanoparticles to reach the surface of the enterocyte, therefore prolonging their 598 
residence at the site of absorption. Another important fact was that the metabolism of 599 
docetaxel appeared to be not affected when it was carried by the nanoparticles (p<0.01). In 600 
fact, the clearance of docetaxel from DTX-NP and pegylated nanoparticles was similar to the 601 
value calculated from the i.v. administration of Taxotere®. Compared to DTX-NP, pegylated 602 
nanoparticles increased the drug elimination half-life, mean residence time (MRT) and 603 
volume of distribution (V) (Table 4). These results would corroborate that when docetaxel is 604 
loaded into pegylated nanoparticles, the drug has sustained release, prolonged half-life and 605 
increased tissue appetency. As a consequence, the relative oral bioavailability obtained for 606 
the different pegylated nanoparticles were high, varying from 24 to 33% for DTX-NP6 and 607 
DTX-NP2 respectively. These bioavailability results are slightly higher than others reported 608 
previously using solid lipid nanoparticles [Cho et al., 2014] or self-nano-emulsifying drug 609 
delivery systems [Seo et al., 2013]. Nevertheless, the bioavailability of docetaxel in pegylated 610 
nanoparticles was lower than the value reported by Feng et al. (2009) with poly(lactide)-611 
vitamin E TPGS/montmorillonite nanoparticles on SD rats (about 90%). 612 
The distribution of the orally administered docetaxel, when loaded into pegylated 613 
nanoparticles, appeared to be quite similar to that elicited by Taxotere® (Figures 5 and 6). 614 
The comparative evaluation of the drug levels in different organs was quite similar for both 615 
intravenous Taxotere® and pegylated nanoparticles; although this similar trend was delayed 616 
in time for the oral treatments. In both cases, docetaxel accumulates in the liver, spleen, 617 
lungs, intestine and kidneys. The main difference, if any, is the decreased levels of docetaxel 618 
observed in the hearts of animals treated orally with pegylated nanoparticles (Figure 6).  619 
All together these results suggest that pegylated nanoparticles, after reaching the surface of 620 
the enterocytes, would release the loaded docetaxel and, in parallel, disturb the effect of P-621 
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gp and cytochrome P450. Obviously, the possibility that these pegylated nanoparticles 622 
penetrate the enterocytes cannot be discarded; although their absorption through the blood 623 
and/or lymphatic routes would be unlikely. This idea would be supported by the similar 624 
elimination (clearance) and distribution of docetaxel in vivo from pegylated nanoparticles 625 
and intravenous Taxotere®. Another factor supporting this explanation would be that these 626 
pegylated nanoparticles when incubated with Caco-2 cells were not capable to be 627 
internalized [Ojer et al., 2013]. In line with this, biodistribution studies of these pegylated 628 
nanoparticles (radiolabelled with technetium-99m) demonstrated that the localization of 629 
these carriers after oral administration was restricted to the gut [Ojer et al., 2012]. It is also 630 
important to take into account that the drug plasma levels are in line with the intestinal cell 631 
renewal cycle, which takes 3–5 days [Barker, 2014]. Furthermore, in an aqueous medium at 632 
neutral/basic pH, the anhydride residues of the polymer used to prepare our nanoparticles 633 
(Gantrez® AN) suffer from hydrolysis yielding carboxylic groups. Under these conditions, the 634 
ionization of these –COOH groups would induce a swelling of the nanoparticle shell 635 
facilitating the drug release and hampering its entry into the cells. In any case, the behaviour 636 
of pegylated nanoparticles would be different to that proposed for PLGA nanocapsules 637 
[Attili-Qadri et al., 2013] or solid lipid nanoparticles [Cho et al., 2014]. In these cases, these 638 
nanodevices would penetrate into the enterocytes and move into the circulation via the 639 
lymphatic system [Attili-Qadri et al., 2013]. Probably, the lipid character of the oily core of 640 
these nanoparticles would favour this particular behaviour. 641 
In summary, pegylated nanoparticles provide an adequate device for the oral delivery of 642 
docetaxel. When orally administered, these nanoparticles offered prolonged and sustained 643 
plasma levels of the anticancer drug for 3 days. In addition, the relative oral bioavailability 644 
was calculated to be up to 32% and between 5 and 6-times higher than for “naked” 645 
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nanoparticles.  Interestingly, the elimination and distribution of docetaxel in vivo from 646 
pegylated nanoparticles and intravenous Taxotere® was found to be similar, suggesting that 647 
these nanoparticles would remain within the gut after reaching the surface of the 648 
enterocytes and would not enter into the circulation.  649 
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Figure Legends 803 
Figure 1. Field emission scanning electron microscopy (FESEM) and energy-filtered 804 
transmision electron microscopy (EFTEM) images of the different poly(anhydride) 805 
nanoparticles loaded with docetaxel. FESEM image of DTX-NP (A), DTX-NP6 (B) and DTX-NP2 806 
(C). EFTEM image of DTX-NP2 (D). 807 
Figure 2. Docetaxel release profiles from the poly(anhydride) nanoparticles formulations 808 
after incubation in simulated gastric fluid (SGF) and simulated intestinal fluid (SIF) at 37°C. 809 
Data represented as mean ± S.D. (n=4). 810 
Figure 3. Docetaxel plasma concentration-time profile after a single intravenous dose in 811 
Balb/c mice (30 mg/kg) dose of the commercially available formulation Taxotere®. Data are 812 
expressed as mean ± S.D., n=4 per time point. 813 
Figure 4. Docetaxel plasma levels as a function of time after the oral administration of 814 
nanoparticle formulations as a single dose of 30 mg/kg bw in Balb/c mice. Data are 815 
expressed as mean ± S.D., n=4 per time point. 816 
Figure 5. Organ distribution time profiles of docetaxel in Balb/c mice after i.v. administration 817 
of Taxotere® (A) or oral administration of docetaxel loaded in pegylated nanoparticles with 818 
either PEG2000 (B) or PEG6000 (C). All mice received a single dose of 30 mg/kg. Data are 819 
expressed as mean ± S.D. (n=4). 820 
Figure 6. Comparative organ distribution of docetaxel following the oral administration of 821 
the different poly(anhydride) nanoparticles loaded with docetaxel and the intravenous 822 
administration of Taxotere® at 8 hours after administration in Balb/c mice. All mice received 823 
a single dose of 30 mg/kg. Data are expressed as mean ± S.D. (n=4). *p<0.05 Taxotere® vs. 824 
nanoparticle formulations: DTX-NP, DTX-NP2 and DTX-NP6. 825 
 826 
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Table 1. Physico-chemical characterization of the poly(anhydride) nanoparticles obtained. 
Data are expressed as mean±S.D. (n=4). NP: control nanoparticles; NP2: control 
pegylated nanoparticles with PEG2000; NP6: control pegylated nanoparticles with 
PEG6000; DTX-NP: docetaxel-loaded nanoparticles; DTX-NP2: docetaxel-loaded in 
pegylated nanoparticles with PEG2000; DTX-NP6: docetaxel-loaded in pegylated 
nanoparticles with PEG6000. 





PDI Yield  
(%) 
PEG content   
(μg/mg) 
DTX loading      
(μg/mg) 
 EE 
     (%) 
NP 167±2 -55±6 0.07 79±3 - - - 
DTX-NP 220±2  -43±1 0.15 65±3 - 60±2 42±4 
NP2 154±3 -42±3 0.05 72±3  36.2±3.1† - - 
DTX-NP2 203±4 -36±4 0.07 62±3 43.8±6.1† 111±3*† 78±9*† 
NP6 157±2 -45±4 0.07 68±1 54.1±2.2 - - 
DTX-NP6 197±3  -33±2 0.08 60±5  56.7±1.9 88±2* 60±2* 
*p<0.05 Mann Whitney U-test DTX-NP2 vs. DTX-NP, DTX-NP6 vs. DTX-NP; † p<0.05 




Table 2. Elemental ratio of the elements and fitting results of the C1s peak of nanoparticle 
formulations. The C-O/C-N components are shown together because they present the 
same position in the C1s spectra (around 286.5 eV) and it is not possible to resolve them 
individually. 
Formulation 
 XPS elemental ratio 
(%)      XPS C1s fitting ratio (%) 
C O N C = O C-O / C-N C-C / C-H 
NP 68 32 0 16 11 42 
NP2 68 32 0 14 19 35 
NP6 71 29 0 15 21 36 
DTX -NP  69 28 3 15 21 33 
DTX-NP2 67 31 2 14 16 37 




Table 3. Kinetic parameters of in vitro release profiles of DTX-loaded nanoparticles. Data 
are expressed as mean ± S.D. (n=4). 
Formulation 
Korsmeyer-Peppas Higuchi Zero-order 
KKP  
(h-n) n r
2 KH  (h-1/2) r
2 Kz  (h-1) r
2 
DTX-NP 0.52±0.02 0.25±0.04 0.98 0.42±0.03 0.87 0.23±0.04 0.28 
DTX-NP2 0.79±0.01 0.10±0.02 0.99 0.72±0.11  0.79 0.5±0.2 0.24 




Table 4. Pharmacokinetic parameters of docetaxel in female Balb/c mice for the different formulations tested. Dose DTX= 30 mg/kg. 
Data are expressed as mean ± S.D. (n=4). 





  MRT 
  (h) 
     T ½ z 
   (h) 
 Cl 





Taxotere® i.v 142.6 ± 1.9 197.9 ± 37.2 0.08   1.4 ± 0.1     1.5 ± 0.1     0.2 ± 0.1 0.5 ± 0.2 100 
Taxotere® p.o N.D N.D N.D    N.D     N.D    N.D N.D N.D 
DTX-NP p.o 6.9 ± 1.6* 1.3 ± 0.4 0.8     4.2 ± 0.2*      2.2 ± 0.3*    0.2 ± 0.1 0.8 ± 0.1* 4.9 
DTX-NP2 p.o 45.9 ± 3.5*† 1.5 ± 0.3 2    43.5 ± 9.8*†      34.7 ± 9.6*†    0.2 ± 0.1 9.6 ± 0.7*† 32.2 
DTX-NP6 p.o 33.8 ± 1.2*† 2.0 ± 0.2 1.5    41.7 ± 2.3*†      34.6 ± 2.5*†    0.2 ± 0.1 8.6 ± 0.7*† 23.7 
AUC: Area under the concentration-time curve from time 0 to t h; Cmax: Peak plasma concentration; Tmax: Time to reach peak 
plasma concentration; t1/2 z: Half-life of the terminal phase; Cl: Clearance; V: Volume of distribution; MRT: Mean residence time; Fr: 
relative oral bioavailability.  *p<0.05 Mann-Whitney U-test DTX-NP vs. Taxotere® i.v., DTX-NP2 vs. Taxotere® i.v., DTX-NP6 vs. 
Taxotere® i.v..† p<0.05 Mann Whitney U-test DTX-NP2 vs. DTX-NP, DTX-NP6 vs. DTX-NP. 
 
Table(s) 4
